Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415586 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29423393 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29493550 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL15480253 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL8904188 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29415589 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL16401903 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558970 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL22283176 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL23138547 | 0.94 | CASP3 (0.58) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| EP-4039280-A1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | Seagen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-12-31 | — | — | US | disclosed |
| EP-3470086-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-11-05 | — | — | US | disclosed |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2020-10-13 | — | — | US | disclosed |
| WO-2015052321-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052533-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052534-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | SPIROGEN SÀRL (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2014130879-A2 | NOVEL ANTIBODY CONJUGATES AND USES THEREOF | STEM CENTRX, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140120118-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2014-05-01 | — | — | US | disclosed |
| EP-2558127-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | Seattle Genetics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD79B, BCL6B, BCL6 | CASP3 3033/4885MDM4 2543/4885TP53 2699/4885 |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | CASP3 2594/4885MDM4 2816/4885TP53 3412/4885 |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | CASP3 3515/4885MDM4 2050/4885TP53 1477/4885 |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | CASP3 2155/4885MDM4 1229/4885TP53 1591/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | CASP3 3033/4885MDM4 2543/4885TP53 2699/4885 |
| US-20140120118-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CLTB, CD79B, BCL6B | CASP3 229/4885MDM4 2882/4885TP53 484/4885 |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD4, IL2 | CASP3 3515/4885MDM4 2050/4885TP53 1477/4885 |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | CASP3 2518/4885MDM4 1900/4885TP53 2607/4885 |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | CASP3 3515/4885MDM4 2050/4885TP53 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.